KR930003908A - 염증, 국소빈혈-유도된 세포의 손상 및 근디스트로피의 치료방법 - Google Patents
염증, 국소빈혈-유도된 세포의 손상 및 근디스트로피의 치료방법 Download PDFInfo
- Publication number
- KR930003908A KR930003908A KR1019910014711A KR910014711A KR930003908A KR 930003908 A KR930003908 A KR 930003908A KR 1019910014711 A KR1019910014711 A KR 1019910014711A KR 910014711 A KR910014711 A KR 910014711A KR 930003908 A KR930003908 A KR 930003908A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- hydrogen
- independently
- integer
- defined above
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
내용 없음.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (3)
- 염증 및 관절염 치료용 약제를 제조하기 위한 하기 일반식(I)의 화합물 또는 그의 약학적으로 허용가능한 염의 용도 :상기식에서, R1및 R2는 서로 독립적으로 수소, C1내지 C6알킬, C1내지 C6알콕시 또는 C1내지 C4알킬(C1내지 C4알킬)이고; R3및 R4는 서로 독립적으로 수소 또는 C1내지 C4알킬이며; n은 0내지 4의 정수이고, m은 0또는 1이고, 단, m 및 n이 둘다 0일수 없으며; R5및 R는 하기 (A) 내지 (C)의 정의중 하나로 정의된다; (A)R5및 R6는 서로 독립적으로 수소, C1내지 C8알킬, C3내지 C8사이클로알킬, C2내지 C8알케닐, C2내지 C8알키닐, - (CH2)qOR7, - (CH2)qN(R7R8), - (CH2)qSR7, - (CH2)r나프틸 또는 - (CH2)r 이며, 여기서 q는 1내지 6의 정수이고, R7및 R8은 서로 독립적으로 수소 또는 C1내지 C4알킬이고, R9는 수소, 할로, C1내지 C4알킬, 트리플루오로메틸, 하이드록시, 아미노, C1내지 C4알킬아미노, 디(C1내지 C4알킬)아미노, 페닐아미노 또는 디페닐아미노이고, r은 0내지 4의 정수이거나; 또는 (B)R5및 R6중 하나는 상기(A)에 정의된 바와 같고, 다른 하나는(여기서, ma, na. R1a, R2a, R3a및 R4a는 각각 m, n, R1, R2, R3및 R4와 동일한 치환체이다)이거나; 또는 (C)R5및 R6는 그들이 결합된 질소원자와 함께또는를 형성하며, 여기서 R4는 상기 정의한 바와 같고, R10은 수소, C1내지 C4알킬,- (CH2)t-COOR7또는 - (CH2)r-N(R7R8) (여기서, R7, R8, R9및 r은 상기 정의한 바와 같고, s 및 t는 서로 독립적으로 0 내지 4의 정수이다)이다.
- 국소빈혈-유도된 세포의 손상방지용 약제를 제조하기 위한 하기 일반식(Ⅱ)의 화합물 또는 그의 약학적으로 허용가능한 염의 용도 :상기식에서, R1및 R2는 서로 독립적으로 수소, C1내지 C6알킬, C1내지 C6알록시 또는 C1내지 C4알킬(C1내지 C4알킬)이고; R3및 R4는 서로 독립적으로 수소 또는 C1내지 C4알킬이며; n은 1내지 4의 정수이고; R5및 R6는 하기 (A) 내지 (C)의 정의중 하나로 정의된다; (A) R5및 R6는 서로 독립적으로 수소, C1내지 C8알킬, C3내지 C8사이클로알킬, C2내지 C8일케닐, C2내지 C8알키닐,- (CH2)q0R7,-(CH2)qN(R7R8), -(CH2)qSR7, -(CH2)r나프틸 또는 -(CH2)r -이며, 여기서 q는 1내지 6의 정수이고, R7및 R8은 서로 독립적으로 수소 또는 C1내지 C4알킬이고, R9는 수소, 할로, C1내지 C4알킬, 트리플루오로메틸, 하이드록시, 아미노, C1내지 C4알킬아미노, 디(C1내지 C4알킬)아미노, 페닐 아미노 또는 디페닐아미노이고, r은 0내지 4의 정수이거나; 또는 (B) R5및 R6중 하나는 상기(A)에 정의된 바와 같고, 다른 하나는(여기서, ma, na, R1a, R2a, R3a및 R4a는 각각 m, n, R1, R2, R3및 R4와 동일한 치환체이다)이거나; 또는 (C)R5및 R6는 그들이 결합된 질소원자와 함께또는를 형성하며, 여기서 R4는 상기 정의한 바와 같고, R10는 수소, C1내지 C4알킬,-COOR7또는 - (CH2)r-N(R7R8) (여기서, R7, R8, R9및 r은 상기 정의한 바와 같고, s 및 t는 서로 서로 독립적으로 0내지 4의 정수이다)이다.
- 근디스트로피 치료용 약제를 제조하기 위한 일반식(Ⅱ)의 화합물 또는 그의 약학적으로 허용가능한 염의 용도;상기식에서, R1및 R2는 서로 독립적으로 수소, C1내지 C6알킬, C1내지 C6알콕시 또는 C1내지 C4알킬(C1내지 C4알킬) 이고; R3및 R4는 서로 독립적으로 수소 또는 C1내지 C4알킬이며; n은 1내지 4의 정수이고; R5및 R6는 하기(A) 내지 (C)의 정의중 하나로 정의된다; (A)R5및 R6는 서로 독립적으로 수소, C1내지 C8알킬, C3내지 C8사이클로알킬, C2내지 C8알케닐, C2내지 C8알키닐, (CH2)q0R7, - (CH2)qN(R7R8), - (CH2)qSR7, - (CH2)r 이고, 여기서, q는 1내지 6의 정수이고, R7및 R8은 서로 독립적으로 수소 또는 C1내지 C4알킬이고, R9는 수소, 할로, C1내지 C4알킬, 트리플루오로메틸, 하이드록시, 아미노, C1내지 C4알킬아미노, 디 (C1내지 C4알킬) 아미노, 페닐아미노 또는 디페닐아미노이고, r은 0 내지 4의 정수이거나; 또는 (B)R5및 R6중 하나는 상기(A)에 정의된 바와 같고, 다른 하나는(여기서, na, R1a, R2a, R3a및 R4a는 각각 n, R1, R2, R3및 R4와 동일한 치환체이다)이거나; 또는 (C)R5및 R6는 그들이 결합된 질소원자와 함께또는를 형성하며, 여기서 R4는 상기 정의한 바와 같고, R10은 수소, C1내지 C4알킬,또는- (CH2)r-N(R7R8) (여기서, R7, R8, R9및 r은 상기 정의한 바와 같고, s 및 t는 서로 독립적으로 0 내지 4의 정수이다)이다.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/572,288 | 1990-08-27 | ||
US07/572,288 US5281623A (en) | 1990-08-27 | 1990-08-27 | Method for treating inflammation |
Publications (1)
Publication Number | Publication Date |
---|---|
KR930003908A true KR930003908A (ko) | 1993-03-22 |
Family
ID=24287162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019910014711A KR930003908A (ko) | 1990-08-27 | 1991-08-24 | 염증, 국소빈혈-유도된 세포의 손상 및 근디스트로피의 치료방법 |
Country Status (9)
Country | Link |
---|---|
US (2) | US5281623A (ko) |
EP (2) | EP0680755A1 (ko) |
JP (1) | JPH04230623A (ko) |
KR (1) | KR930003908A (ko) |
AU (1) | AU643062B2 (ko) |
CA (1) | CA2049902A1 (ko) |
HU (1) | HUT61662A (ko) |
TW (1) | TW199094B (ko) |
ZA (1) | ZA916556B (ko) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4426245A1 (de) | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
DE4436127A1 (de) * | 1994-09-27 | 1996-03-28 | Deutsches Rheumaforschungszent | Verwendung von aromatischen Amiden und Säuren zur Behandlung von rheumatischen Erkrankungen |
JPH08198756A (ja) * | 1995-01-23 | 1996-08-06 | Minsei Kagaku Kyokai | 筋ジストロフィー進行抑制剤 |
US5633283A (en) * | 1995-01-23 | 1997-05-27 | Eli Lilly And Company | Method for treating multiple sclerosis |
US6028111A (en) * | 1996-03-08 | 2000-02-22 | Oxigene, Inc. | Compositions and use of benzamides and nicotinamides as anti-inflammatory agents |
US20060275370A1 (en) * | 2002-07-25 | 2006-12-07 | Yih-Lin Chung | Method and compositions for treatment of epithelial damage |
US8883148B2 (en) * | 2002-04-26 | 2014-11-11 | Asan Laboratories Company (Cayman), Limited | Prevention of joint destruction |
US8846039B2 (en) * | 2002-04-26 | 2014-09-30 | Asan Laboratories Company (Cayman), Limited | Method for ameliorating pruritus |
US6809118B2 (en) * | 2002-07-25 | 2004-10-26 | Yih-Lin Chung | Methods for therapy of radiation cutaneous syndrome |
US8946295B2 (en) * | 2002-07-25 | 2015-02-03 | Sunny Pharmtech Inc. | Histone hyperacetylating agents for promoting wound healing and preventing scar formation |
US8163764B2 (en) * | 2002-04-26 | 2012-04-24 | Asan Laboratories Company (Cayman) Limited | Skincare methods |
WO2014190250A1 (en) * | 2013-05-23 | 2014-11-27 | The Johns Hopkins University | Activators of soluable guanylate cyclase and their use in treatment of duchenne muscular dystrophy and related disease |
US10730886B2 (en) * | 2015-09-04 | 2020-08-04 | Shin Poong Pharmaceutical Co., Ltd. | Compound having effect of inhibiting platelet aggregation and salt thereof, and composition for preventing or treating thrombotic diseases, containing same |
US10449198B2 (en) | 2016-07-01 | 2019-10-22 | The University Of Liverpool | Method for treating pain |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3043774A (en) * | 1955-09-23 | 1962-07-10 | Ethyl Corp | Organic compositions |
NL281258A (ko) * | 1961-07-28 | 1900-01-01 | United States Rubber Co | |
US3305483A (en) * | 1964-12-03 | 1967-02-21 | Ethyl Corp | Stabilized organic compositions |
US3809761A (en) * | 1970-03-12 | 1974-05-07 | Ethyl Corp | Method for reducing plasma lipid levels |
US3714365A (en) * | 1970-03-12 | 1973-01-30 | Ethyl Corp | Reducing abnormally high plasma lipid levels in mammals with phenols |
US3792170A (en) * | 1972-03-14 | 1974-02-12 | Merck & Co Inc | Novel alkylsulfinyl derivatives for pain,fever and inflammation |
DE2240609A1 (de) * | 1972-08-18 | 1974-02-28 | Hoechst Ag | Stoffwechselwirksame derivate der 4-hydroxy-3,5-di-alkylphenyl-propionsaeure |
GB1405767A (en) * | 1972-12-14 | 1975-09-10 | Ethyl Corp | Method formulation and pharmaceutical composition for reducing plasma lipid levels |
US3994828A (en) * | 1973-06-07 | 1976-11-30 | Dynapol Corporation | Nonabsorbable antioxidant |
US4116930A (en) * | 1975-11-03 | 1978-09-26 | Ciba-Geigy Corporation | Pyromellitic dimiides of 3,5-dialkyl-4-hydroxyphenylsubstituted amines |
JPS52125170A (en) * | 1976-04-12 | 1977-10-20 | Yoshitomi Pharmaceut Ind Ltd | Pyridine derivatives |
US4128664A (en) * | 1977-05-16 | 1978-12-05 | Riker Laboratories, Inc. | Substituted benzamides as anti-inflammatory agents |
US4324717A (en) * | 1980-06-23 | 1982-04-13 | The B. F. Goodrich Company | Norbornene polymers stabilized with hindered aromatic alcohols |
US4562201A (en) * | 1982-07-26 | 1985-12-31 | American Hospital Supply Corporation | Aminomethyl benzanilides |
GB8301754D0 (en) * | 1983-01-21 | 1983-02-23 | Fisons Plc | Formulation |
IT1194325B (it) * | 1983-07-19 | 1988-09-14 | Simes | Composizioni farmaceutiche comprendenti epinina o un suo sale farmaceuticamente accettabile e loro uso terapeutico |
JPS6061523A (ja) * | 1983-09-16 | 1985-04-09 | Shionogi & Co Ltd | 経口用ドブタミン製剤 |
US4532356A (en) * | 1983-11-16 | 1985-07-30 | Ethyl Corporation | Chemical process |
JPS61106545A (ja) * | 1984-10-31 | 1986-05-24 | Yamanouchi Pharmaceut Co Ltd | 4−(ω−アミノアルキル)ピロカテコ−ル |
ES8704873A1 (es) * | 1985-01-15 | 1987-04-16 | Glaxo Group Ltd | Un procedimiento para la preparacion de 3,4-dihidroxifemetilamino derivados 2-ustituidos. |
GB8501646D0 (en) * | 1985-01-23 | 1985-02-27 | Nipa Lab Ltd | Control of micro-organisms |
GB8603765D0 (en) * | 1986-02-15 | 1986-03-19 | Beecham Wuelfung Gmbh & Co Kg | Compounds |
US5036157A (en) * | 1986-03-11 | 1991-07-30 | Burroughs Wellcome Co. | Aryl derivatives |
US4959503A (en) * | 1986-04-11 | 1990-09-25 | Warner-Lambert Company | Diarylalkanoids having activity as lipoxygenase inhibitors |
US4708966A (en) * | 1986-06-27 | 1987-11-24 | The Procter & Gamble Company | Novel anti-inflammatory agents, pharmaceutical compositions and methods for reducing inflammation |
IT1204416B (it) * | 1986-06-27 | 1989-03-01 | Midy Spa | Medicamenti a base di analoghi di feniletanolammine per il trattamento di disturbi gastro-intestinali ed uterini |
US4861798A (en) * | 1986-12-29 | 1989-08-29 | Bristol-Myers Company | Lipoxygenase inhibitory compounds |
US5171882A (en) * | 1987-01-12 | 1992-12-15 | Eli Lilly And Company | Leukotriene antagonists |
JPS63185923A (ja) * | 1987-01-28 | 1988-08-01 | Otsuka Pharmaceut Factory Inc | 抗炎症剤 |
DE3702755A1 (de) * | 1987-01-30 | 1988-08-11 | Hoechst Ag | 3,5-di-tert.-butyl-4-hydroxybenzoesaeureamid, verschiedene von dessen derivaten, verfahren zur herstellung dieser verbindungen, die sie enthaltenden arzneimittel und ihre verwendung |
DK123788A (da) * | 1987-03-10 | 1988-09-11 | Beecham Group Plc | Morpholin-derivater |
DE3855801T2 (de) * | 1987-09-15 | 1997-07-03 | Rowett Research Inst | Anwendungsgebiete von beta-adrenergenen Agonisten |
US4948813A (en) * | 1987-11-30 | 1990-08-14 | E. I. Du Pont De Nemours And Company | Benzylketone phospholipase A2 inhibitors |
US5108363A (en) * | 1988-02-19 | 1992-04-28 | Gensia Pharmaceuticals, Inc. | Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist |
US5039805A (en) * | 1988-12-08 | 1991-08-13 | Hoffmann-La Roche Inc. | Novel benzoic and phenylacetic acid derivatives |
DE3903989A1 (de) * | 1989-02-10 | 1990-09-20 | Basf Ag | Diphenylheteroalkylderivate, ihre herstellung und daraus hergestellte arzneimittel und kosmetika |
EP0385043A1 (en) * | 1989-02-28 | 1990-09-05 | Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. (Faes) | New derivatives of 4-substituted piperazines |
-
1990
- 1990-08-27 US US07/572,288 patent/US5281623A/en not_active Expired - Fee Related
-
1991
- 1991-08-19 ZA ZA916556A patent/ZA916556B/xx unknown
- 1991-08-20 TW TW080106603A patent/TW199094B/zh active
- 1991-08-22 EP EP95202001A patent/EP0680755A1/en not_active Withdrawn
- 1991-08-22 EP EP19910307721 patent/EP0476846A3/en not_active Withdrawn
- 1991-08-23 AU AU82783/91A patent/AU643062B2/en not_active Ceased
- 1991-08-24 KR KR1019910014711A patent/KR930003908A/ko not_active Application Discontinuation
- 1991-08-26 CA CA002049902A patent/CA2049902A1/en not_active Abandoned
- 1991-08-26 HU HU912793A patent/HUT61662A/hu unknown
- 1991-08-26 JP JP3213543A patent/JPH04230623A/ja not_active Withdrawn
-
1993
- 1993-12-02 US US08/161,821 patent/US5393786A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP0680755A1 (en) | 1995-11-08 |
HU912793D0 (en) | 1992-01-28 |
AU643062B2 (en) | 1993-11-04 |
US5281623A (en) | 1994-01-25 |
EP0476846A2 (en) | 1992-03-25 |
ZA916556B (en) | 1993-04-28 |
HUT61662A (en) | 1993-03-01 |
CA2049902A1 (en) | 1992-02-28 |
AU8278391A (en) | 1992-03-05 |
TW199094B (ko) | 1993-02-01 |
JPH04230623A (ja) | 1992-08-19 |
EP0476846A3 (en) | 1992-08-05 |
US5393786A (en) | 1995-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR920003968A (ko) | 염증성 장 질환의 치료방법 | |
KR930003908A (ko) | 염증, 국소빈혈-유도된 세포의 손상 및 근디스트로피의 치료방법 | |
CA2012686A1 (en) | Treatment and compounds | |
KR870006016A (ko) | N-벤조일 우레아 화합물, 이를 함유하는 항종양 조성물 및 그의 제조 방법 | |
ES463408A1 (es) | Procedimiento para la preparacion de nuevas fluoracil-resor-cinas sustituidas. | |
KR920016089A (ko) | 제i형 당뇨병의 치료방법 | |
ES8200011A1 (es) | Procedimiento de preparacion de una composicion farmaceuticaen particular psicotropa. | |
GR3004250T3 (ko) | ||
ES460040A1 (es) | Un procedimiento para preparar derivados de 4-hidroxifeni- lalcanolaminas. | |
CA2002834A1 (en) | Cycloalkyl xanthines | |
UA37311C2 (uk) | Засіб для лікування статевої дисфункції і фармацевтичний препарат | |
EP0210140A3 (en) | Inhibitors of benzylaminoxidases, selective with respect to other aminoxidases | |
KR830004219A (ko) | 약리적 활성 펩티드 | |
KR830004218A (ko) | 약리적 활성 펩티드 | |
KR920014818A (ko) | 항균제 | |
ES467743A1 (es) | Un procedimiento para preparar nuevos derivados de bencila- mina | |
MX9206930A (es) | Nuevos compuestos | |
KR900016210A (ko) | 신규 화합물 | |
KR910000645A (ko) | 개선된 경련치료제 | |
ES459755A1 (es) | Procedimiento para preparar carbamatos de oximas de deriva- dos del acido isonitrosocianocetico. | |
IL69448A (en) | Process for combating phytopathogenic fungi with azolylphenoxy-tetrahydrofuran-2-ylidene methane derivatives | |
IE790108L (en) | Isoquinoline compounds | |
JPS5675428A (en) | Hypoglycemic agent containing procainamide hydrochloride | |
GB1095220A (en) | Novel benzdiaz[1,4]epine derivatives and a process for the manufacture thereof | |
CA2054738A1 (en) | 15-deoxyprostaglandin derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |